---
title: "Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule"
date: "2025-02-11 15:09:18"
summary: "Richard Drury  I covered Aclaris (NASDAQ:ACRS) in September 2023, and the stock has dropped nearly 70% since then. The stock saw a major spike in December 2024, however it is now trading down from those highs. As I noted before, Aclaris has a"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Five stacks of coloured coins with a graph line above](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w750) 



Richard Drury





I [covered](https://seekingalpha.com/article/4637873-aclaris-therapeutics-many-lives-of-biopharmaceutical-developer) Aclaris (NASDAQ:[ACRS](https://seekingalpha.com/symbol/ACRS "Aclaris Therapeutics, Inc.")) in September 2023, and the stock has dropped nearly 70% since then. The stock saw a major spike in December 2024, however it is now trading down from those highs. As I noted before, Aclaris has a

[seekalpha_articles](https://seekingalpha.com/article/4756932-aclaris-therapeutics-history-of-failures-and-recent-acquisition-of-a-blockbuster-potential-molecule)
